Medical Device Reporting for Manufacturers; Guidance for Industry and Food and Drug Administration Staff; Availability, 78603-78605 [2016-26933]
Download as PDF
mstockstill on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 81, No. 216 / Tuesday, November 8, 2016 / Notices
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–N–3362 for ‘‘Intent to Review a
Study Data Standardization Plan
Template.’’ Received comments will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
VerDate Sep<11>2014
16:27 Nov 07, 2016
Jkt 241001
78603
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
all matters regarding the use of the
PhUSE SDSP template.
FOR FURTHER INFORMATION CONTACT:
II. Electronic Access
Crystal Allard, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 21, Rm. 1518,
Silver Spring, MD 20993–0002, 301–
796–8856, crystal.allard@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
BILLING CODE 4164–01–P
FDA is a participating member of
PhUSE, an independent, non-profit
consortium of academic, regulatory,
non-profit, and private sector entities.
PhUSE provides a global platform for
the discussion of topics encompassing
the work of biostatisticians, data
managers, statistical programmers, and
e-clinical information technology
professionals, with the mission of
providing an open, transparent, and
collaborative forum to address
computational science issues. As part of
this collaboration, PhUSE working
groups develop and periodically publish
proposals for enhancing the review and
analysis of human and animal study
data submitted to regulatory agencies.
You can learn more about PhUSE
working groups at https://www.phuse.eu/
cs-working-groups.aspx. (FDA has
verified the Web site addresses as of the
date this document publishes in the
Federal Register, but Web sites are
subject to change over time.)
In December 2014, FDA published the
Study Data Technical Conformance
Guide (the ‘‘Guide,’’ available at https://
www.fda.gov/ForIndustry/
DataStandards/StudyDataStandards/
default.htm), which contains technical
recommendations to sponsors for the
submission of animal and human study
data and related information in a
standardized electronic format. In
section 2.1 of the Guide, FDA
recommends that sponsors should
include a plan (e.g., in the IND)
describing the submission of
standardized study data to FDA. FDA’s
Study Data Standards Resources Web
page provides recommendations for
preparing an SDSP (https://www.fda.gov/
downloads/ForIndustry/DataStandards/
StudyDataStandards/UCM447119.pdf).
FDA now intends to review the
PhUSE SDSP template, a deliverable of
the working group effort described
previously in this document, with the
potential result that FDA could
recommend the use of the template in
its current form, or in a modified form,
for use in the regulatory submission of
study data in conformance with the
Guide. FDA invites public comment on
Frm 00039
Fmt 4703
Dated: November 2, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–26913 Filed 11–7–16; 8:45 am]
I. Background
PO 00000
The PhUSE SDSP template is
available at: https://www.phusewiki.org/
wiki/images/e/ea/SDSP_Template.pdf.
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–D–0743]
Medical Device Reporting for
Manufacturers; Guidance for Industry
and Food and Drug Administration
Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA) is announcing the
availability of the guidance entitled
‘‘Medical Device Reporting for
Manufacturers; Guidance for Industry
and Food and Drug Administration
Staff.’’ This guidance document is
intended to assist medical device
manufacturers meet applicable reporting
and recordkeeping requirements for
certain device-related adverse events
and malfunctions.
DATES: Submit either electronic or
written comments on this guidance at
any time. General comments on Agency
guidance documents are welcome at any
time.
ADDRESSES: You may submit comments
as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov/ will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
E:\FR\FM\08NON1.SGM
08NON1
78604
Federal Register / Vol. 81, No. 216 / Tuesday, November 8, 2016 / Notices
mstockstill on DSK3G9T082PROD with NOTICES
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2013–D–0743 for ‘‘Medical Device
Reporting for Manufacturers’’. Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION’’. The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
VerDate Sep<11>2014
16:27 Nov 07, 2016
Jkt 241001
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
An electronic copy of the guidance
document is available for download
from the Internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the guidance
document entitled ‘‘Medical Device
Reporting for Manufacturers’’ to the
Office of the Center Director, Guidance
and Policy Development, Center for
Devices and Radiological Health, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 5431,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to
assist that office in processing your
request.
FOR FURTHER INFORMATION CONTACT:
Isaac Chang, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 3114, Silver Spring,
MD 20993–0002, 301–796–2789.
SUPPLEMENTARY INFORMATION:
I. Background
Medical device reporting under
section 519(a) of the Federal Food Drug,
and Cosmetic Act (21 U.S.C. 360i(a))
provides a mechanism that allows FDA
and device manufacturers, user
facilities, and importer of medical
devices to identify and monitor adverse
events (deaths and serious injuries) and
certain malfunctions involving your
medical devices. The goal is to detect
and correct problems in a timely
manner. This guidance updates FDA’s
policy and clarifies FDA’s
interpretations of the regulatory
requirements under part 803 (21 CFR
part 803) and includes a section on
common reporting errors.
The draft of this guidance was made
available in the Federal Register on July
9, 2013 (78 FR 41069), and the comment
period closed October 7, 2013. FDA
reviewed and considered all public
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
comments received and revised the
guidance as appropriate.
This document supersedes the draft
entitled, ‘‘Medical Device Reporting for
Manufacturers; Guidance for Industry
and Food and Drug Administration
Staff,’’ dated July 9, 2013, and the
previous guidance on this topic,
‘‘Medical Device Reporting for
Manufacturers,’’ issued March 1997.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the current
thinking of FDA on medical device
reporting. It does not establish any
rights for any person and is not binding
on FDA or the public. You can use an
alternative approach if it satisfies the
requirements of the applicable statutes
and regulations.
III. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by
downloading an electronic copy from
the Internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.regulations.gov. Persons
unable to download an electronic copy
of ‘‘Medical Device Reporting for
Manufacturers; Guidance for Industry
and Food and Drug Administration
Staff’’ may send an email request to
CDRH-Guidance@fda.hhs.gov to receive
an electronic copy of the document.
Please use the document number 1828
to identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR parts 801 and 809, regarding
labeling, have been approved under
OMB control number 0910–0485; the
collections of information in part 803,
regarding medical device reporting,
have been approved under OMB control
number 0910–0437; the collections of
information in 21 CFR part 806,
regarding corrections and removals,
have been approved under OMB control
number 0910–0359; the collections of
information in 21 CFR part 807, subpart
E, regarding premarket notification,
E:\FR\FM\08NON1.SGM
08NON1
Federal Register / Vol. 81, No. 216 / Tuesday, November 8, 2016 / Notices
have been approved under OMB control
number 0910–0120; the collections of
information in 21 CFR part 812,
regarding investigational device
exemptions, have been approved under
OMB control number 0910–0078; the
collections of information in 21 CFR
part 814, subparts A through E,
regarding premarket approval, have
been approved under OMB control
number 0910–0231; the collections of
information in 21 CFR part 820,
regarding quality system regulations,
have been approved under OMB control
number 0910–0073; the collections of
information regarding MedWatch: The
Food and Drug Administration Medical
Products Reporting Program have been
approved under OMB control number
0910–0291; and the collections of
information regarding the Adverse
Event Program for Medical Devices
(Medical Product Safety Network
(MedSun)) have been approved under
OMB control number 0910–0471.
Dated: November 3, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–26933 Filed 11–7–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–D–0075]
Non-Inferiority Clinical Trials To
Establish Effectiveness; Guidance for
Industry; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a
guidance for industry entitled ‘‘NonInferiority Clinical Trials to Establish
Effectiveness.’’ This document provides
guidance to sponsors and applicants
submitting investigational new drug
applications (INDs), new drug
applications (NDAs), biologics licensing
applications (BLAs), or supplemental
applications on the appropriate use of
non-inferiority (NI) study designs to
provide evidence of the effectiveness of
a drug or biologic. The guidance gives
advice on when NI studies
demonstrating effectiveness of an
investigational drug can provide
interpretable results, how to choose the
NI margin, and how to test the NI
hypothesis.
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:27 Nov 07, 2016
Jkt 241001
Submit either electronic or
written comments on Agency guidances
at any time.
ADDRESSES: You may submit comments
as follows:
DATES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2010–D–0075 for ‘‘Non-Inferiority
Clinical Trials to Establish
Effectiveness; Guidance for Industry.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
78605
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
Submit written requests for single
copies of this guidance to the Division
of Drug Information, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10001 New
Hampshire Ave., Hillandale Building,
4th Floor, Silver Spring, MD 20993–
0002 or the Office of Communication,
Outreach and Development, Center for
Biologics Evaluation and Research
(CBER), Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 71,
Rm. 3128, Silver Spring, MD 20993–
0002. Send one self-addressed adhesive
label to assist that office in processing
your requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the guidance document.
FOR FURTHER INFORMATION CONTACT:
Scott Goldie, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
E:\FR\FM\08NON1.SGM
08NON1
Agencies
[Federal Register Volume 81, Number 216 (Tuesday, November 8, 2016)]
[Notices]
[Pages 78603-78605]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-26933]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-D-0743]
Medical Device Reporting for Manufacturers; Guidance for Industry
and Food and Drug Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of the guidance entitled ``Medical Device Reporting for
Manufacturers; Guidance for Industry and Food and Drug Administration
Staff.'' This guidance document is intended to assist medical device
manufacturers meet applicable reporting and recordkeeping requirements
for certain device-related adverse events and malfunctions.
DATES: Submit either electronic or written comments on this guidance at
any time. General comments on Agency guidance documents are welcome at
any time.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov/
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note
[[Page 78604]]
that if you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2013-D-0743 for ``Medical Device Reporting for Manufacturers''.
Received comments will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION''. The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
An electronic copy of the guidance document is available for
download from the Internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the guidance document entitled
``Medical Device Reporting for Manufacturers'' to the Office of the
Center Director, Guidance and Policy Development, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your request.
FOR FURTHER INFORMATION CONTACT: Isaac Chang, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 3114, Silver Spring, MD 20993-0002, 301-796-2789.
SUPPLEMENTARY INFORMATION:
I. Background
Medical device reporting under section 519(a) of the Federal Food
Drug, and Cosmetic Act (21 U.S.C. 360i(a)) provides a mechanism that
allows FDA and device manufacturers, user facilities, and importer of
medical devices to identify and monitor adverse events (deaths and
serious injuries) and certain malfunctions involving your medical
devices. The goal is to detect and correct problems in a timely manner.
This guidance updates FDA's policy and clarifies FDA's interpretations
of the regulatory requirements under part 803 (21 CFR part 803) and
includes a section on common reporting errors.
The draft of this guidance was made available in the Federal
Register on July 9, 2013 (78 FR 41069), and the comment period closed
October 7, 2013. FDA reviewed and considered all public comments
received and revised the guidance as appropriate.
This document supersedes the draft entitled, ``Medical Device
Reporting for Manufacturers; Guidance for Industry and Food and Drug
Administration Staff,'' dated July 9, 2013, and the previous guidance
on this topic, ``Medical Device Reporting for Manufacturers,'' issued
March 1997.
II. Significance of Guidance
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
current thinking of FDA on medical device reporting. It does not
establish any rights for any person and is not binding on FDA or the
public. You can use an alternative approach if it satisfies the
requirements of the applicable statutes and regulations.
III. Electronic Access
Persons interested in obtaining a copy of the guidance may do so by
downloading an electronic copy from the Internet. A search capability
for all Center for Devices and Radiological Health guidance documents
is available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance
documents are also available at https://www.regulations.gov. Persons
unable to download an electronic copy of ``Medical Device Reporting for
Manufacturers; Guidance for Industry and Food and Drug Administration
Staff'' may send an email request to CDRH-Guidance@fda.hhs.gov to
receive an electronic copy of the document. Please use the document
number 1828 to identify the guidance you are requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR parts 801 and 809, regarding
labeling, have been approved under OMB control number 0910-0485; the
collections of information in part 803, regarding medical device
reporting, have been approved under OMB control number 0910-0437; the
collections of information in 21 CFR part 806, regarding corrections
and removals, have been approved under OMB control number 0910-0359;
the collections of information in 21 CFR part 807, subpart E, regarding
premarket notification,
[[Page 78605]]
have been approved under OMB control number 0910-0120; the collections
of information in 21 CFR part 812, regarding investigational device
exemptions, have been approved under OMB control number 0910-0078; the
collections of information in 21 CFR part 814, subparts A through E,
regarding premarket approval, have been approved under OMB control
number 0910-0231; the collections of information in 21 CFR part 820,
regarding quality system regulations, have been approved under OMB
control number 0910-0073; the collections of information regarding
MedWatch: The Food and Drug Administration Medical Products Reporting
Program have been approved under OMB control number 0910-0291; and the
collections of information regarding the Adverse Event Program for
Medical Devices (Medical Product Safety Network (MedSun)) have been
approved under OMB control number 0910-0471.
Dated: November 3, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-26933 Filed 11-7-16; 8:45 am]
BILLING CODE 4164-01-P